A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
Simultaneous p53 and p16 Immunostaining for Molecular Subclassification of Head and Neck Squamous Cell Carcinomas
Tekijät: Pakkanen, Pihla; Silvoniemi, Antti; Aro, Katri; Bäck, Leif; Irjala, Heikki; Aaltonen, Leena-Maija; Hagström, Jaana; Haglund, Caj; Laine, Jukka; Minn, Heikki; Huvila, Jutta
Kustantaja: SPRINGER
Kustannuspaikka: NEW YORK
Julkaisuvuosi: 2024
Journal: Head and Neck Pathology
Tietokannassa oleva lehden nimi: HEAD & NECK PATHOLOGY
Lehden akronyymi: HEAD NECK PATHOL
Artikkelin numero: 73
Vuosikerta: 18
Numero: 1
Sivujen määrä: 10
ISSN: 1936-055X
eISSN: 1936-0568
DOI: https://doi.org/10.1007/s12105-024-01680-z
Verkko-osoite: https://doi.org/10.1007/s12105-024-01680-z
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/457612077
Purpose
Our aim was to assess the ability of simultaneous immunohistochemical staining (IHC) for p16 and p53 to accurately subclassify head and neck squamous cell carcinomas (HNSCC) as HPV-associated (HPV-A) versus HPV-independent (HPV-I) and compare p53 IHC staining patterns to TP53 mutation status, p16 IHC positivity and HPV status.
Methods
We stained 31 HNSCCs for p53 and p16, and performed next-generation sequencing (FoundationOne (c) CDx) on all cases and HPV in-situ hybridization (ISH) when sufficient tissue was available (n = 23). p53 IHC staining patterns were assessed as wildtype (wt) or abnormal (abn) patterns i.e. overexpression, null or cytoplasmic staining.
Results
In a majority of cases (28/31) interpretation of p16 and p53 IHC was straightforward; 10 were considered HPV-A (p16+/p53wt) and 18 cases were HPV-I (p16-/p53abn). In the remaining three tumours the unusual immunophenotype was resolved by molecular testing, specifically (i) subclonal p16 staining and wild type p53 staining in a tumour positive for HPV and with no TP53 mutation (HPV-A), (ii) negative p16 and wild type p53 staining with a TP53 mutation and negative for HPV (HPV-I), and (iii) equivocally increased p16 staining with mutant pattern p53 expression, negative HPV ISH and with a TP53 mutation (HPV-I).
Conclusion
Performing p16 and p53 IHC staining simultaneously allows classification of most HNSCC as HPV-A (p16 +, p53 wild type (especially basal sparing or null-like HPV associated staining patterns, which were completely specific for HPV-A SCC) or HPV-I (p16 -, p53 mutant pattern expression), with the potential for limiting additional molecular HPV or mutational testing to selected cases only.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
This work was funded by Helsinki University Hospital Research Funds (LMA), The Finnish Medical Foundation (AS), Cancer Society of Finland and Finnish Government Research Funding (MH). Roche provided the FoundationOne® CDx test assays. Open Access funding provided by University of Turku (including Turku University Central Hospital).